

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A06/2016 OS WB

DISPATCHED ON 07TH JUNE 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A3; B8, B64; Cw7, Cw8; DR15, DR17; DQ2, DQ6

			Summary of Results								
			PBL/T-Cells				B-Cells				
Total tested			18	18	18	16	14	14	12	14	
Positive			1	0	0	7	14	0	4	13	
Negative			17	18	18	9	0	14	8	1	
NT/Equivocal			1	1	1	3	2	2	4	2	
% Positive			5.6%	0.0%	0.0%	43.8%	100.0%	0.0%	33.3%	92.9%	
% Negative			94.4%	100.0%	100.0%	56.3%	0.0%	100.0%	66.7%	7.1%	
<b>Consensus</b>			<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Not Assessed</b>	<b>Positive</b>	<b>Negative</b>	<b>Not Assessed</b>	<b>Positive</b>	
HLA Antibody Specificity (Defined By CDC)			B12, DQ1	DR7	B40, B13, B47	A2, A28, A9	B12, DQ1	DR7	B40, B13, B47	A2, A28, A9	
			Without DTT				Without DTT				
Lab No.	PBL/T Cell Assessment	B Cell Assessment	Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	Comments
101	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Positive	
114	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	Delayed delivery
116	YES	YES	Positive	Negative	Negative	Positive	Positive	Negative	Equivocal	Positive	
117	YES	NO	Negative	Negative	Negative	Equivocal					
133	YES	YES	Negative	Negative	Negative	Negative	NT	NT	NT	NT	Cell viability too low
136	YES	NO	Negative	Negative	Negative	Positive					
145	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Negative	
149	YES	NO	Negative	Negative	Negative	Negative					
162	YES	YES	Negative	Negative	Negative	Positive	Positive	Negative	Positive	Positive	
163	YES	YES	Negative	Negative	Negative	Positive	Positive	Negative	Positive	Positive	
186	YES	YES	Negative	Negative	Negative	Positive	Positive	Negative	Positive	Positive	
204	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Equivocal	Positive	
206	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
212	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Positive	
227	YES	YES	Negative	Negative	Negative	NT	Positive	Negative	Negative	Positive	Technical failure
268	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Positive	
284	YES	YES	Negative	Negative	Negative	Positive	Positive	Negative	Negative	Positive	
311	YES	YES	Negative	Negative	Negative	Positive	Positive	Negative	Negative	Positive	
315	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Positive	

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A06/2016 OS WB

DISPATCHED ON 07TH JUNE 2016

Lab No.	PBL/T-cell without DTT				B-cell without DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101	1	1	1	2	6	1	1	6		100	100
114	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
116	4	1	1	6	8	1		8	88	97	80
117	1	1	1								
133	0	0	0	0	NT	NT	NT	NT		80	30
136	1	1	1	8						90	
145					8					100	100
149									70		
162				4/6	8		4/6	8		100	100
163	1	1	1	6	8	1	6	8		98	98
186	0	0	0	2	8	0	6	8		99	99
204	1	1	1	1	8	2	4	8		90	85
206	1	1	1	1	8	1	8	8		80	80
212									99	97	98
227					8			8	90	90	90
268	1	1	1	1	8	1	1	8		98	98
284	1	1	1	8	8	1	1	8		98	96
311	1	1	1	6	8	1	1	8		100	85
315	1	1	1	1	8	1	1	8	80	80	80

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITHOUT DTT OF SAMPLE 2A06/2016 OS WB

DISPATCHED ON 07TH JUNE 2016

Lab No.	Summary of Results															
	PBL				PBL Without DTT				T-Cells				T-Cells Without DTT			
	Without DTT				Serum 1	Serum 2	Serum 3	Serum 4	Without DTT				Serum 1	Serum 2	Serum 3	Serum 4
	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength
162	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Positive				4/6
268									Negative	Negative	Negative	Negative	1	1	1	1
284									Negative	Negative	Negative	Positive	1	1	1	8

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A06/2016 OS WB

DISPATCHED ON 07TH JUNE 2016

HLA PHENOTYPE OF BLOOD DONOR: HLA-A2, A3; B8, B64; Cw7, Cw8; DR15, DR17; DQ2, DQ6

	Summary of Results							
	PBL/T-Cells				B-Cells			
Total tested	14	14	14	13	13	13	11	13
Positive	1	0	0	6	11	0	3	12
Negative	13	14	14	7	2	13	8	1
NT/Equivocal	2	2	2	3	2	2	4	2
% Positive	7.1%	0.0%	0.0%	46.2%	84.6%	0.0%	27.3%	92.3%
% Negative	92.9%	100.0%	100.0%	53.8%	15.4%	100.0%	72.7%	7.7%
<b>Consensus</b>	<b>Negative</b>	<b>Negative</b>	<b>Negative</b>	<b>Not Assessed</b>	<b>Positive</b>	<b>Negative</b>	<b>Not Assessed</b>	<b>Positive</b>
HLA Antibody Specificity (Defined By CDC)	B12, DQ1	DR7	B40, B13, B47	A2, A28, A9	B12, DQ1	DR7	B40, B13, B47	A2, A28, A9

Lab No.	PBL/T Cell Assessment	B Cell Assessment	With DTT				With DTT				Comments
			Serum 1	Serum 2	Serum 3	Serum 4	Serum 1	Serum 2	Serum 3	Serum 4	
101	YES	YES	Negative	Negative	Negative	Negative	<b>Negative</b>	Negative	Negative	Positive	Delayed delivery
114	YES	YES	NT	NT	NT	NT	NT	NT	NT	NT	
116	YES	YES	<b>Positive</b>	Negative	Negative	Positive	Positive	Negative	<b>Equivocal</b>	Positive	Cell viability too low
133	YES	YES	Negative	Negative	Negative	Negative	NT	NT	NT	NT	
149	YES	NO	NT	NT	NT	NT					
162	YES	YES	Negative	Negative	Negative	Positive	Positive	Negative	Negative	Positive	Technical failure
163	YES	YES	Negative	Negative	Negative	Positive	Positive	Negative	Positive	Positive	
186	YES	YES	Negative	Negative	Negative	Positive	Positive	Negative	Positive	Positive	
204	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	<b>Equivocal</b>	Positive	
206	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Positive	Positive	
212	YES	YES	Negative	Negative	Negative	Negative	<b>Negative</b>	Negative	Negative	<b>Negative</b>	
227	YES	YES	Negative	Negative	Negative	NT	Positive	Negative	Negative	Positive	
268	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Positive	
284	YES	YES	Negative	Negative	Negative	Positive	Positive	Negative	Negative	Positive	
311	YES	YES	Negative	Negative	Negative	Positive	Positive	Negative	Negative	Positive	
315	YES	YES	Negative	Negative	Negative	Negative	Positive	Negative	Negative	Positive	

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A06/2016 OS WB

DISPATCHED ON 07TH JUNE 2016

Lab No.	PBL/T-cell with DTT				B-cell with DTT				Cell viability %		
	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	Serum 1 reaction strength	Serum 2 reaction strength	Serum 3 reaction strength	Serum 4 reaction strength	PBL	T-cells	B-cells
101	1	1	1	2	1	1	1	4		100	100
114	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT	NT
116	2	1	1	6	8	1		8		97	80
133	0	0	0	0	NT	NT	NT	NT		80	30
149									70		
162				4	6			8		100	100
163	1	1	1	6	8	1	6	8		98	98
186	0	0	0	2	8	0	6	8		99	99
204	1	1	1	2	8	2	4	8		90	85
206	1	1	1	1	8	1	8	8		80	80
212									99	97	98
227					8			8	90	90	90
268	1	1	1	1	8	1	1	8		98	98
284	1	1	1	4	8	1	1	8		98	96
311	1	1	1	6	8	1	1	8		100	85
315	1	1	1	1	8	1	1	8	80	80	80

**UK NEQAS for H&I Scheme 2A - Cytotoxic Crossmatching**

PBL/T-CELL AND B-CELL CROSSMATCHING RESULTS WITH DTT OF SAMPLE 2A06/2016 OS WB

DISPATCHED ON 07TH JUNE 2016

Lab No.	Summary of Results															
	PBL				PBL With DTT				T-Cells				T-Cells With DTT			
	With DTT				Serum 1	Serum 2	Serum 3	Serum 4	With DTT				Serum 1	Serum 2	Serum 3	Serum 4
	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength	Serum 1	Serum 2	Serum 3	Serum 4	reaction strength	reaction strength	reaction strength	reaction strength
162	NT	NT	NT	NT	NT	NT	NT	NT	Negative	Negative	Negative	Positive				4
268									Negative	Negative	Negative	Negative	1	1	1	1
284									Negative	Negative	Negative	Positive	1	1	1	4